Predicting the Outcome of Treatment De-Escalation or Discontinuation: What Do We Know?

Predicting the Outcome of Treatment De-Escalation or Discontinuation: What Do We Know? is organized by Cleveland Clinic Center for Continuing Education and will be held from Jun 05, 2017 - Jun 05, 2019.

Target Audience
The online series is designed for rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, and associated allied health practitioners, including nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and inflammatory disorders.

Accreditation:
The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Description
Biologic Therapies VII: Precision Medicine in the Biologic Era online series brings together world leaders in immune-based therapies and addresses cutting-edge translational immunology and the latest data on biologic therapeutics.

Predicting the Outcome of Treatment De-Escalation or Discontinuation: What Do We Know? will review the key factors that influence the outcome of studies assessing treatment tapering along with guidelines for the treatment of rheumatoid arthritis.

Learning Objectives:
• Identify the key factors that influence the outcome of studies assessing treatment tapering.
• Explain the differences in study design for published studies on TNFi discontinuation.
• Discuss the concerns at the patient level when therapies are adjusted.

Additional details will be posted as soon as they are available.